Concepedia

Andre H Crepaldi

AH

Statistics

Publications

10

Citations

1.6K

H-Index

10

Active since

2017

Affiliations

Janssen (United States)(Current)

Matsuyama Red Cross Hospital

National and Kapodistrian University of Athens

Seoul National University

Medical University of Silesia

Andre H Crepaldi is an author at Janssen (United States) specializing in multiple myeloma therapy, medicine, and multiple myeloma.

Publications per year

2017–2025

10

Publications

10

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 984 citations · Full text

, , +17

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 438 citations · Full text

, , +14

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 56 citations · Full text

, , +17

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · Blood · 2019 · 25 citations

, , +17

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Stefan Knop, María‐Victoria Mateos, Meletios Α. Dimopoulos et al. · BMC Cancer · 2021 · 23 citations · Full text

, , +17

1–5 of 10